Latest news with #Zacks-ranked
Yahoo
3 days ago
- Business
- Yahoo
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -229.41%. A quarter ago, it was expected that this developer of cell therapies would post a loss of $0.51 per share when it actually produced a loss of $0.67, delivering a surprise of -31.37%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Plus , which belongs to the Zacks Medical - Drugs industry, posted revenues of $1.06 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 42.76%. This compares to year-ago revenues of $1.68 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Plus shares have lost about 75.1% since the beginning of the year versus the S&P 500's gain of 0.5%. While Plus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Plus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.17 on $1.9 million in revenues for the coming quarter and -$0.67 on $8.23 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, IGC Pharma, Inc. (IGC), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. IGC Pharma, Inc.'s revenues are expected to be $0.31 million, up 6.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report IGC Pharma, Inc. (IGC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Business
- Yahoo
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates
Nutriband Inc. (NTRB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 7.69%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.18, delivering a surprise of -50%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Nutriband , which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.67 million for the quarter ended April 2025, missing the Zacks Consensus Estimate by 6.06%. This compares to year-ago revenues of $0.41 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Nutriband shares have added about 37.2% since the beginning of the year versus the S&P 500's gain of 0.5%. While Nutriband has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Nutriband: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $0.76 million in revenues for the coming quarter and -$0.56 on $14.09 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Plus Therapeutics (PSTV), has yet to report results for the quarter ended March 2025. This developer of cell therapies is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of +77.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Plus Therapeutics' revenues are expected to be $1.85 million, up 10.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nutriband Inc. (NTRB) : Free Stock Analysis Report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Zscaler (ZS) Tops Q3 Earnings and Revenue Estimates
Zscaler (ZS) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.88 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 12%. A quarter ago, it was expected that this cloud-based information security provider would post earnings of $0.69 per share when it actually produced earnings of $0.78, delivering a surprise of 13.04%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Zscaler , which belongs to the Zacks Security industry, posted revenues of $678.03 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 1.75%. This compares to year-ago revenues of $553.2 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Zscaler shares have added about 40.6% since the beginning of the year versus the S&P 500's gain of 0.1%. While Zscaler has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Zscaler: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.75 on $707.18 million in revenues for the coming quarter and $3.06 on $2.65 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Security is currently in the top 13% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, CrowdStrike Holdings (CRWD), is yet to report results for the quarter ended April 2025. The results are expected to be released on June 3. This cloud-based security company is expected to post quarterly earnings of $0.66 per share in its upcoming report, which represents a year-over-year change of -29%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. CrowdStrike Holdings' revenues are expected to be $1.1 billion, up 19.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Zscaler, Inc. (ZS) : Free Stock Analysis Report CrowdStrike (CRWD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Gap (GAP) Q1 Earnings and Revenues Surpass Estimates
Gap (GAP) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.91%. A quarter ago, it was expected that this clothing chain would post earnings of $0.36 per share when it actually produced earnings of $0.54, delivering a surprise of 50%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Gap , which belongs to the Zacks Retail - Apparel and Shoes industry, posted revenues of $3.46 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 1.33%. This compares to year-ago revenues of $3.39 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Gap shares have added about 19.5% since the beginning of the year versus the S&P 500's gain of 0.1%. While Gap has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Gap: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.59 on $3.75 billion in revenues for the coming quarter and $2.32 on $15.3 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Apparel and Shoes is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Vera Bradley (VRA), another stock in the same industry, has yet to report results for the quarter ended April 2025. The results are expected to be released on June 11. This handbag and accessories company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of +38.1%. The consensus EPS estimate for the quarter has been revised 50% lower over the last 30 days to the current level. Vera Bradley's revenues are expected to be $53.92 million, down 33.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Gap, Inc. (GAP) : Free Stock Analysis Report Vera Bradley, Inc. (VRA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Elastic (ESTC) Q4 Earnings and Revenues Surpass Estimates
Elastic (ESTC) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 27.03%. A quarter ago, it was expected that this software developer would post earnings of $0.47 per share when it actually produced earnings of $0.63, delivering a surprise of 34.04%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Elastic , which belongs to the Zacks Internet - Software industry, posted revenues of $388.43 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.20%. This compares to year-ago revenues of $335 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Elastic shares have lost about 6.8% since the beginning of the year versus the S&P 500's gain of 0.1%. While Elastic has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Elastic: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.43 on $393.05 million in revenues for the coming quarter and $2.11 on $1.67 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Paychex (PAYX), another stock in the same industry, has yet to report results for the quarter ended May 2025. This payroll processor and human-resources services provider is expected to post quarterly earnings of $1.20 per share in its upcoming report, which represents a year-over-year change of +7.1%. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. Paychex's revenues are expected to be $1.38 billion, up 6.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Elastic N.V. (ESTC) : Free Stock Analysis Report Paychex, Inc. (PAYX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
